ページ5 - 最高の乳房生検医師 - トップ161名の医師

Professional experience

2007. Director of the Assisted Reproduction Unit of the Quironsalud University Hospital of Madrid since its opening.

2004-06 Private consultation on assisted reproduction in Madrid.

1994-96. Deputy Physician. Department of Gynecology and Obstetrics. Hospital 12 de Octubre, Madrid.

Membership in scientific societies

-He is a member of the Spanish Society of Gynecology and Obstetrics (SEGO).

-Spanish Society of Fertility (SEF);

-European Society of Human Reproduction (ESHRE)

-American Society for Reproductive Medicine (ASRM).

Research and Teaching

In recent years, he has conducted over 30 conferences, 20 presentations and 15 talks at courses and conferences in his specialty. He has written 5 book chapters and coordinated 4 monographs.

2010 Associate Professor. European University of Madrid.

2004-07 Professor of Master in Human Reproduction. Spanish Fertility Society and Complutense University.

1990-98 Professor, PhD student. Training Center for Medical Specialists (CTO)

Assoc. Prof. Ayşe İrem Yasin, M.D., is a medical oncologist who specializes in solid tumors. Her clinical focus includes breast, lung, gastrointestinal, gynecologic, and urologic cancers. She also treats brain and other CNS tumors, soft tissue sarcomas, head and neck cancers, adenocarcinomas, melanoma, Merkel cell carcinoma, and cancers of unknown primary. She practices at Medipol Acıbadem District Hospital (2025–present). She previously worked at Şişli Etfal Training and Research Hospital (2023–2025).

She completed a Medical Oncology fellowship at Bezmialem Vakıf University (2019–2022). This followed an Internal Medicine residency at the same institution (2012–2016). Her international experience includes the Breast Cancer Unit at the University of Piemonte Orientale in Novara (2022). She also trained at Basel University Hospital, Cleveland Clinic, and Harvard Medical School. She holds the ESMO Board Certificate (2022).

アントニオ・デ・ラシー・フォルトゥニー博士は、25年の経験を持つがん外科医です。医師は、直腸と結腸のがん治療、減量手術、食道がんの治療を専門としています。

この外科医は15,000を超える外科手術を行ってきました。デ・ラシー博士は、毎年1,000件以上の介入を、低侵襲技術（腹腔鏡手術およびロボット手術）を使用して実施しています。

アントニオ・デ・ラシー博士は、国際医療コミュニティ、学会、協会のメンバーです。彼はヨーロッパの外科医-内視鏡医協会の会長を務めています。この医師は、先進技術と腹腔鏡手術の研究に関する国際コースの講師です。

デ・ラシー・フォルトゥニー博士は、消化器外科手術の世界的に有名なパイオニアの一人とされています。彼は以下のような外科技術を初めて実施した外科医です：

• デ・ラシー博士は、口を通して胆嚢を取り除く世界で初めての専門家になりました。入院後3日目に患者が退院しました。
• 2010年に、この医師は大腸をを取り除く世界で最初の医師となりました。
• この医師は、結腸および直腸がんのための腹腔鏡手術の創始者です。2009年に新しい技術TaTME（経肛門的全直腸間膜切除術）を用いて、世界で初めて直腸の摘出手術を行いました。今、彼は外科医に知識を提供し、教えています。
• デ・ラシー・フォルトゥニー博士は、自然の開口部を通じて腹腔へのアクセスを提供する経管的内視鏡外科手術（NOTES）方法のパイオニアです。

Prof. Jong Kyun Lee is among best gastroenterologist in South Korea and Asia.

Specialty

Professor Jong Kyun Lee specializes in the management of pancreatic, bile duct and gallbladder cancers, pancreatitis, gallstones.

Work experience

Gastroenterologist at Samsung Medical Center.

Education

• The Seoul National University College of Medicine (South Korea)
• The University of California (USA).

Membership in organizations

• The Korean Society of Gastrointestinal Endoscopy
• The Korean Society of Gastroenterology
• The Korean Pancreatobiliary Association.

Professor Kyu Taek Lee is a top gastroenterologist from South Korea.

Specialty

Professor Kyu Taek Lee is a GI specialist in the management of pancreatic, bile duct and gallbladder cancers.

Work experience

• Gastroenterology specialist of the Department of Gastroenterology at Samsung Medical Center.

Education

• Hanyang University College of Medicine (South Korea)
• Stanford University School of Medicine (USA)
• Kyoto Second Red Cross Hospital (Japan).

Membership in organizations

• The Korean Society of Gastrointestinal Endoscopy
• The Korean Society of Gastroenterology.

Oncogynecologist

Oncologist

Gynecologist. Oncogynecologist

Oncosurgeon, Head of Samsung Department of Urology

Urologist, Oncosurgeon

Areas of Interests

• Genital Laser Application ( Vajinal  Rejuvenation , Laser Incontinence Treatment)
• Aesthetic  Genital  Surgery ( Labioplastia, Vaginoplastia, Perineoplastia )
• Vaginismus Treatment.
• Treatment Of Female Sexual Function Disorders.
• Hormonal & Non-Hormonal Treatment.
• Laser Incontinence Treatment.
• Medical Treatment İn Incontinence.

Education

• Hacettepe  University  Faculty of  Medicine, ANKARA.
• SBÜ. ANKARA Dr. Zekai Tahir Burak  Training and  Research  Hospital.

Experience

• SBÜ.ANKARA Dr. Zekai Tahir Burak Training and Research Hospital.
• Antalya Training and  Research  Hospital,
• Jinefem , Private Gynecology Center, ANTALYA
• SM Clinic, Private Gynecology Center, ANTALYA
• Liv Hospital Ulus, İSTANBUL

Research:

• Gestational  Diabetic  Evaluation of  Affinity in Pregnant  Woman in Turkey.
• The  Effect of Intrauterin Insemination on  Pregnancy  Rates in Infertile Woman in 456 cycles.
• The  Effect of  Genital  Laser  Applications on  Urinary  Incontinence  Treatment.
• The  Effect of  Genital  Laser  Applications  on  Vaginal  Atrofi  in  Menopause.
• Distribution of Human Papilloma Virus (HPV) İnfection in the Mediterranean Region in Turkey.

Areas of Interests

• Breast cancer
• Lung cancer
• Colorectal cancers
• Gynecological and urogenital cancers
• Molecular Oncology

Education:

• Kızıltepe Anatolian High School 2001
• Dicle University Faculty of Medicine 2007
• Istanbul Medeniyet University Göztepe Training and Research Hospital 2014
• Kartal City Hospital 2021
• Associate Professor of Medical Oncology 2023

Experience:

• Liv Hospital Ulus
• Adıyaman University Training and Research Hospital
• Istanbul Umraniye Training and Research Hospital
• Istanbul Umraniye Training and Research Hospital

Research:

• Phase II, Randomized, Open-Label, Multicenter Study to Comparatively Evaluate the Efficacy and Safety of GDC-9545 and Physician-Preferred Endocrine Monotherapy in Previously Treated, Estrogen Receptor Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer Patients, Other ( International), Dr. Murat Ayhan
• Phase III, Randomized, Evaluating the Efficacy and Safety of Palbociclib and Fulvestrant with Gdc-0077 Compared with Placebo in Patients with Pik3ca-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer. Double Blind, Placebo Controlled Study, Other (International), Dr. Murat Ayhan
• Randomized, Multicenter, Phase Ib/III Study Evaluating the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Atezolizumab Compared to Intravenous Atezolizumab in Patients with Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer, Other (International) Dr. Murat Ayhan
• Randomized, Controlled, Multicenter, Open-Label Study Including Observation Follow-Up for PSMA-PET-Negative Patients, Investigating the Efficacy and Safety of Addition of Apalutamide to Radiotherapy and LHRH Agonist in PSMA-PET-Positive High-Risk Hormone-Sensitive Prostate Cancer Patients, Other (International) Dr. Murat Ayhan
• Biomarker Study to Identify Patients with Advanced Stage Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations-42756493BLC0002, Other (International), Dr. Murat Ayhan
• Publications:
• Ayhan M, Turan N, Köstek O, et all. Does the efficacy of regorafenib differ in chemotherapy refractory metastatic colorectal cancer patients who had mucinous pathology compared to those who had non-mucinous pathology? Curr Probl Cancer. 2021 Jun;45(3):100670. doi: 10.1016/j.currproblcancer.2020.100670.
• Ayhan M, Odabas H, Turan N, et all. Factors affecting the mortality rate of patients with cancer hospitalized with COVID-19: a single center's experience. J Chemother. 2021 Nov;33(7):499-508. doi: 10.1080/1120009X.2021.1923153.
• Ayhan M, Laçin Ş, Özyükseler DT, et all. Does systemic anti-tumor therapy increase COVID-19 risk in patients with cancer? J Oncol Pharm Pract. 2021 Sep;27(6):1461-1467. doi: 10.1177/10781552211015762.
• Ayhan M, Abamor E, Coban Kokten S, et al. Value of FDG PET/CT in Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer. EJMI 2022;6(2):165–175.
• Ayhan M, Terzioglu K. Experience With Rapid Drug Desensitization With Chemotherapeutics; A SingleCentre Retrospective Study. EJMI 2021;5(3):380–387.
• Doğan A, AYHAN M. Survival analysis of patients with triple-negative breast cancer: a single-center experience. Journal of Oncological Sciences, 8(2), 94-99., Doi: 10.37047/jos.2022-89749
• Terzioğlu K, Ayhan M. Comparative Assessment of Platinum Salts and Taxane Group Hypersensitivity Reactions, The Role of Skin Tests in Diagnosis? J Oncol Pharm Pract. 2021 Nov 30:10781552211050084. doi: 10.1177/10781552211050084.
• Tacar SY, Selcukbiricik F, Yilmaz M, Erturk K, Murat Sarici A, Gulturk I, Ayhan M, Tural D. Nivolumab for metastatic uveal melanoma: a multicenter, retrospective study. Melanoma Res. 2021 Oct 1;31(5):449-455. doi: 10.1097/CMR.0000000000000744.
• Özyurt E, Özçelik S, Sürmeli H, Çelik M, Ayhan M, Özçelik M. Side effects of immune-checkpoint inhibitors: Can multiple side effects be seen in a patient? J Oncol Pharm Pract. 2022 Mar;28(2):462-465. doi: 10.1177/10781552211038136.
• Dülgar Ö, Öven BB, Atcı MM, Arıkan R, Ay S, Ayhan M, Selvi O, Ozyukseler DT, Bayram E, Özcan E, Yasin Aİ, Gümüş M. Is the benefit of using adjuvant capecitabine in patients with residual triple-negative breast cancer related to pathological response to neoadjuvant chemotherapy? Expert Rev Anticancer Ther. 2022 Jul;22(7):773-780. doi: 10.1080/14737140.2022.2076670.
• Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study. J Cancer Res Clin Oncol. 2022 Jun;148(6):1501-1508. doi: 10.1007/s00432-021-03748-7.
• Volume I, Kucukarda A, Atcı MM, Ayhan M, et all. Efficacy and safety of trastuzumab emtansine in older patients with HER2-positive advanced breast cancer: a real-world study. Tumori. 2022 Feb;108(1):19-25. doi: 10.1177/03008916211037739.
• Dogan I, Ayhan M, Gurbuz M, et all. The frequency and prognostic significance of ABO/Rh blood groups in male breast cancer patients: A multicenter study. Medicine (Baltimore). 2022 Sep 2;101(35):e30147. doi: 10.1097/MD.0000000000030147.
• Ozcelik M, Oyman A, Cil I, Duzgun O, Ozkan OF, Ayhan M. Cytoreductive Surgery versus Systemic Chemotherapy alone in Isolated Peritoneal Carcinomatosis of Colorectal Origin. J Coll Physicians Surg Pak. 2021 Nov;31(11):1308-1313. doi: 10.29271/jcpsp.2021.11.1308.
• Başoğlu T, Sakin A, Erol C, Ayhan M, et all. Real life experienceof patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: a Turkish oncology group study. J Chemother. 2022 May 17:1-8. doi: 10.1080/1120009X.2022.2073159.
• Özdemir Ö, Zengel B, Yildiz Y, Ayhan M, et all. The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study. Anticancer Drugs. 2022 Aug 1;33(7):663-670. doi: 10.1097/CAD.0000000000001310.
• Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study). J Cancer Res Clin Oncol. 2022 Sep 1. doi: 10.1007/s00432-022-04252-2.
• Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study. Future Oncol. 2022 Jul;18(23):2573-2582. doi: 10.2217/fon-2022-0083.
• Topcu A, Atci MM, Secmeler S, Besiroglu M, Ayhan M, Ozkan M, Bozkurt O, Urakci Z, Ay S, Geredeli C, Yasin AI, Turk HM. Efficacy of trastuzumab and potential risk factors on survival in patients with HER2-positive metastatic gastric cancer. Future Oncol. 2021 Nov;17(31):4157-4169. doi: 10.2217/fon-2021-0398.
• Bilgin B, Sendur MAN, Yucel S, Ayhan M, et all. Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study. J Cancer Res Clin Oncol. 2021 Jul;147(7):2145-2152. doi: 10.1007/s00432-020-03501-6.
• Atci MM, Akagunduz B, Demir M, Arikan R, Ay S, Ozer M, Ayhan M, Cil I, Demir N, Ozyurt N, Karakaya G, Cevik GT, Onder AH, Selvi O, Sakin A. The impact of adjuvant oxaliplatin and tumor sidedness on the overall survival of stage IIB colon cancer patients: a multicentre study. J Chemother. 2023 Feb;35(1):19-28. doi: 10.1080/1120009X.2022.2040770.
• Tataroglu Ozyukseler D, Ay S, Turan M, Alkan G, Ayhan M, Surmeli H, et al. The Systemic Inflammation Response Index as a Prognostic Marker in Advanced Pancreatic Cancer. EJMI 2022;6(3):367–373.
• Yıldız F, Ayhan M, Demir H, et all. Comparing the efficacy of cabazitaxel in secondline and third-Line treatment of metastatic castration-resistant prostate cancer: a multi-center experience from Turkey. International Journal of Contemporary Medical Research, 7(9), 112-116.,Doi: 10.21276/ijcmr.2020.7.9.30
• Terzioğlu K, Ayhan M. Distribution of allergens detected on patch tests of patients with allergic contact dermatitis and investigation of their atopic background. Annals of Medical Research, 29(5), 422-426., doi: 10.5455/annalsmedres.2021.07.490
• Arikan R, Atci MM, Ay S, Ayhan M, et all Prognostic significance of mucinous histology in left sided metastatic colorectal cancers with wild type RAS and evaluation of backbone chemotherapy regimens. Oncol Lett. 2023 Apr 5;25(5):208. doi: 10.3892/ol.2023.13795.
• Almuradova E, Yalcin S, Arıkan R, Ayhan M, Demir H, Cevik GT, Karaca M, Petekkaya I, Karabulut B. Survival of Patients With Metastatic Rectum Cancer Who Underwent Metastasectomy Following Conversion Chemotherapy Sans Pelvic Radiotherapy: A Turkish Oncology Group Study. Cureus 2023 May 17;15(5):e39119. doi: 10.7759/cureus.39119.
• Topcu A, Besiroglu M, Atci MM, Ayhan M, et all. Second-line Therapy after Trastuzumab Failure in HER2-Positive Metastatic Gastric Cancer: A Real-life Data. EJMI 2023;7(2):153–161. DOI: 10.14744/ejmi.2023.22720
• Book Writing:
• Drug interactions and side effects of targeted agents, Section name: (Small molecule tyrosine kinase inhibitors; ROS-1 targeted therapies (Crizotinib, Seritinib)) (2021)., AYHAN MURAT, Turkish Clinics Journal of Medical Sciences, Editor: Mehmet Aliustaoglu, Publishing number:1, Number of Pages 92, ISBN:978-625-401- 466-6, Turkish
• Approach to gastrointestinal stromal tumors and neuroendocrine tumors, Department name: (Medical approach in primary non-gastrointestinal neuroendocrine tumors) (2020)., AYHAN MURAT, Akademisyen Yayınevi, Editor: Anılır Ender, Number of editions: 1, Number of Pages 382, ISBN: 9786052585719, Turkish
• Internal medicine emergencies, Department name: (Oncological emergencies) (2022)., YILDIRIM SEDAT, AYHAN MURAT, Efe Academic Publishing, Editor: Serdar Olt, Number of editions: 1, Number of Pages 232, ISBN: 978-625-8324-66- 2, Turkish
• Physicians' chemotherapy cancer drug manual 2020, Section name: (Common chemotherapy regimens in clinical practice) (2022)., SÜMBÜL AHMET TANER, ALKAN ALI, AKSOY ASUDE, AYHAN MURAT, et all, Türkiye Klinikleri Journal of Medical Sciences, Editor: EDWAR CHU, VINCENT T. DEVITA, SAADDETIN KILIÇKAP, CEMIL BILIR, SELÇUK SEBER, Number of editions: 1, Number of pages 772, ISBN: 978-625-401-290- 7, Turkish (Book Translation)

Areas of Interests

• Infertility
• In Vitro Fertilization (IVF) Treatment
• Endometriosis
• Urogynecology (urinary incontinence and uterine prolapse surgeries)
• Gynecological Laparoscopic surgeries
• Hysteroscopic surgeries
• Pregnancy Monitoring
• Myoma surgery
• Ovarian cysts and surgeries
• Gynecological plastic surgeries

Education:

• Ataturk University Faculty of Medicine - Undergraduate
• Abant Izzet Baysal University Faculty of Medicine Gynecology and Obstetrics - Specialization
• Bezmialem Vakif University Faculty of Medicine Istanbul - Assistant Professorship
• Bezmialem Vakif University Faculty of Medicine Istanbul - Associate Professorship
• American Hospital - Assisted Reproductive Specialist Training

Experience:

• Bolu Izzet Baysal State Hospital (Compulsory Service) -Bolu
• Bezmialem Vakif University Faculty of Medicine - Istanbul

Marmara University Faculty of Medicine, Department of Radiation Oncology Specialization training: 2012 -2016

Marmara University Faculty of Medicine (English) Undergraduate: 2004-2011

Sixteen Numbered Shirvan School (Azerbaijan) High School: 1998 -2004

Education

Cumhuriyet University Faculty of Medicine, 2004
Istanbul Haydarpaşa Training and Research Hospital Internal Medicine Residency, 2010
Karadeniz Technical University Faculty of Medicine Medical Oncology Residency, 2015

Experience

MD Andeson Cancer Center, USA, 2008
Sunnybrook Odette Cancer Center Breast Cancer Clinic, Canada, 2017
Moffit Cancer Center , USA 2022
Istanbul Haydarpaşa Training and Research Hospital Internal Medicine, 2010
İdil State Hospital Internal Medicine Clinic, 2011
Karadeniz Technical Universityniversitesi Faculty of Medicine, Medical Oncology Clinic, 2015
Istanbul Göztepe Training and Research Hospital, Medical Oncology Clinic, 2018
Yeniyüzyıl University Gaziosmanpaşa Hospital, Medical Oncology Clinic, 2020
Ataşehir Medicana Hospital, Medical Oncology Clinic, 2022

Scientific Membership

Turkish Medical Association (TTB)
Turkish Society of Medical Oncology (TTOD)
European Society for Medical Oncology (ESMO)
American Society of Medical Oncology (ASCO)

Medical Intrests

• Breast Cancer
• Lung Cancer
• Colon Cancer
• Stomach Cancer
• Rectal Cancer
• Ovarian Cancer
• Liver Cancer
• Oesophageal Cancer - Oesophageal Cancer
• Kidney Cancer
• Larynx Cancer - Cancer of the Larynx
• Thyroid Cancer
• Head and Neck Cancers
• Gynaecological Cancers
• Pancreatic Cancer
• Oesophageal Cancer - Oesophageal Cancer
• Uterine Cancer
• Brain Cancers - Brain Tumours
• Soft Tissue Cancer - Sarcomas
• Prostate Cancer
• Bladder Cancer
• Bile Tract Cancer
• Testicular Cancer
• Cervical Cancer
• Mouth, Tongue, Lip Cancers
• Gastrointestinal System Cancers
• Bone Tumours
• Trachea and Bronchial Cancers
• Skin Cancers - Skin Cancers
• Skeletal System Tumours
• Gallbladder Cancer
• Mesothelioma

Dr. Jelena is a Specialist Obstetrician & Gynecologist with over 25 years of experience in her field. She began her medical studies in 1986 at the University of Belgrade Medical School, Belgrade. She completed her primary Medical Degree in 1992 and continued with her internship the following year at the Clinical Centre of Serbia while working as a General Practitioner.

Dr. Jelena has worked at the Gynecology & Obstetrics Clinic Narodni front (Belgrade, Serbia), Special Gynecology Hospital Genesis Medical (Belgrade, Serbia) and General Hospital ST MEDICA (Belgrade, Serbia).

She also worked for two years as a Professor in Gynaecology & Obstetrics for students of the High Medical School, Belgrade, Serbia. She held a post as a Consultant in Gynaecology & Obstetrics for several private clinics in Belgrade.
In April 2016, she moved to Dubai where she started to work as Gynaecology & Obstetrics Specialist.

She specialises in Gynaecological and Obstetrical Ultrasound (4D ultrasound), Gynaecology Endocrinology, Lower Genital Tract Pathology, Hysteroscopy, Prenatal and Post-natal care, Antiaging Treatment, Laser Treatment for Stress Urinary Inconsistency and Vaginal Relaxation Syndrome, Laser Vaginal Tightening, Laser Vaginal Rejuvenation/Vaginal Atrophy Laser Treatment, Invasive and Non-Invasive Gynaecological Diagnosis (HSSG, SIS, HSG) & Aesthetic Gynaecology.

Education

Istanbul University Cerrahpaşa Faculty of Medicine, 2002
Istanbul Fatih Sultan Mehmet Training and Research Hospital, Internal Medicine, 2010
Istanbul University Oncology Institute (Çapa), Medical Oncology, 2015
Medipol University Faculty of Medicine, Phytotherapy Education, 2018
University of Health Sciences, Vocational School of Health, Molecular Oncology, PhD Program, PhD, 2023

Experience

University Hospital, Newark, New Jersey, USA, Observer (2003-2004)
Siirt State Hospital, Internal Medicine (2010-2011)
Siirt State Hospital, Medical Oncology (2015)
Bakırköy Dr. Sadi Konuk Training and Research Hospital, Medical Oncology (2015-2018)
Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Medical Oncology, (Professor Doctor) (2018-Present)
Forensic Medicine 3. Specialization Board, Medical Oncology, Full Member (2019-Present)
Liv Hospital, Ulus, Park-time, Medical Oncology (2020-2022)
Şişli Kolan International Hospital, Park-time, Medical Oncology (2022-2023)

Medical Intrests

• Gastrointestinal System Tumours (Esophagus - Stomach and Large Bowel Cancer)
• Hepatobiliary System Tumours (Liver-Biliary Tract and Pancreatic Cancer)
• Breast Cancer
• Lung Cancer
• Genitourinary Cancers
• Immunotherapies and Target Therapies
• Molecular Oncology
• Immunotherapies
• Target Treatments
•  

Awards

2010-YDUS (Subspecialty Examination) 14th place in Turkey
2014- Oncology Institute Days Best Poster Award
2015- Turkish Medical Oncology Society Board Exam Qualification
2015- ESMO (European Society for Medical Oncology) Board Exam Qualification

Since January 1993, Dr. Totaro holds the role of the Coordinator of the MAP (Medically Assisted Procreation) Center and of the Obstetrics-Gynecological Ultrasound Center at the Ospedale Santa Maria at the Maternal and Child Department. Under his supervision the Center, one of the leading MAR centers in Italy, performs more than 1,000 procedures a year. Ospedale Santa Maria - is in first position, for number of cycles of IUI, intrauterine insemination (586) - level I technique, while for the number of oocyte thawing procedures - level II and III technique - the hospital of Santa Maria from Bari occupies the 4th place in the national ranking.

In 1986 Dr. Totaro graduated in Medicine and Surgery from the University of Bari, Italy with full marks, where 4 years later he specialized in Gynecology and Obstetrics. He then completed his diploma with participation at numerous professional courses, such as "Biophysical and biochemical monitoring of the fetus" (one year course, 1991, Bari) and obtaining a diploma in Clinical Sexuology from the ELEUSIS – International Center for the study, research and therapy of female, male and couple sexual dysfunctions (two years course, 1996, Bari). 

In order to broaden his knowledge in the obstetrics-gynecological scientific field, Dr. Totaro participates, both as moderator and speaker and as organizer, in numerous conferences, symposiums, congresses and courses (over 40 national and international congresses) and is the author of more than 30 scientific publications. 

Dr. Totaro is an active member of the following organizations:

ESHRE (European Society of Human Reproduction and Embryology)

SIRU (Italian Society of Human Reproduction)

SIGO (Italian Society of Gynecology and Obstetrics)

AOGOI (Italian Association of Hospital Obstetricians and Gynecologists)

SIMOP (Italian Society of Private Hospital Doctors)

ESG (European Society of Gynecology).

(現代甲状腺学と腹腔鏡手術)。

ケマル・ラシャ博士は、アナドル医療センター、コジャエリの経験豊富な一般外科医であり、彼の専門分野で23年の経験を有しています。彼の主なポイントは次のとおりです：

• 一般外科、手術感染症、乳がん、甲状腺/副甲状腺手術、高度な低侵襲手術、膵臓がん、グルコース代謝を専門とする
• 1990年にハジェッテペ大学医学部を卒業
• 1996年にハジェッテペ大学医学部で一般外科の専門訓練を受けた
• ヨーロッパ手術感染症学会、世界手術感染症学会、世界緊急手術学会、トルコ医学会、トルコ外科学会を含む様々な団体との積極的な提携
• 彼の功績となる出版物がある。

医学的関心と活動 

• 泌尿器がん学 • ロボット支援腹腔鏡泌尿器手術 • 腹腔鏡的泌尿器科 • 経皮的腎手術 • 内視鏡的泌尿器科 • 泌尿婦人科学

会員資格 

• トルコ泌尿器学会 • 内視鏡泌尿器科学会 • トルコ男科学学会 • 内視鏡泌尿器科協会 • ヨーロッパ泌尿器科学会 (EAU) • アメリカ泌尿器科学会 (AUA) 

研究および出版物 

• 31件の国際出版物 • 22件の国内出版物 • 2件のトルコの書籍セクション • 71件の国際および国内通知